PPT-Prevention of Recurrent VTE in Cancer- Potential Guideline Updates

By Cole Smith PharmD Candidate 2021 Outline Background on Coagulopathy and Cancer Current VTE treatment guideline recommendations Important trials influencing current recommendations New Caravaggio Study 032020. Charles . Levenback. , MD. Professor and Deputy Chair for Patient Care. Gynecologic Oncology Center Medical Director. Lisa Kidin, RN, MSN, MHA. Sr. Business Systems Analyst. Deep vein thrombosis (DVT):. Updates and Clarification to the Process. This NetLearning is meant to clarify common confusion regarding the VTE Prophylaxis Process. . If you did not attend a Meaningful Use Class or take the original NetLearning, “Meaningful Use Mandatory NetLearning”, please view both to ensure that you understand the process completely!. Ten. Venous Disease Coalition. Hypercoagulability. VTE . T. oolkit. Thrombophilia. = . Hypercoagulability. . Deficiencies of:. . . . Antithrombin. . Protein C. . Protein S. Thromboembolism. N . Engl. J Med. 2012;366:1959-67. VTE Prevalence. Incidence . of DVT: 48 per 100,000. Incidence of PE: 23 per 100,000. Case-fatality rate. Inpatient: 12%. 1-year: 19%; 3-year: 30%. FOR DEVELOPING BLOOD . CLOTS (. VTE. ) IN CANCER. What is VTE?. VTE means venous thromboembolism. VTE is a blood clot that can form inside of . your veins. In some cases, the clot becomes big enough to block the blood flow. (EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS. PGY2 Cardiology Resident. WakeMed. Health & . Hosptials. Raleigh, NC. Dr. . Ryan Sparks (presenter). Current PGY2 Cardiology Resident at . WakeMed. CHEST Guidelines 2016. Jennifer . Mah. , MD. March 2016. Case. A 44-year-old man is evaluated in follow-up for an episode of unprovoked left proximal leg deep venous thrombosis 3 months ago. Following initial anticoagulation with low-molecular-weight heparin, he began treatment with . Charles . Levenback. , MD. Professor and Deputy Chair for Patient Care. Gynecologic Oncology Center Medical Director. Lisa Kidin, RN, MSN, MHA. Sr. Business Systems Analyst. Deep vein thrombosis (DVT):. Presented by. Faculty/Presenter Disclosure. Faculty:. Relationships with commercial interests:. Disclosure of Commercial Support. This program has received financial support from Sanofi Canada, in the form of an educational grant.. . for. . Cancer. . Outpatients. . on. . Chemotherapy. :. . Case . study. Carme Font, MD. Medical . Oncology. . Department. Barcelona. Spain. Primary . Pregnancy for women with complex needs. Maternity service update. Antenatal VTE assessment. Dr Lauren Ward – CCG clinical lead for preconception and antenatal care. Background – venous thromboembolism. Thrombosis Fellow. VTE is chronic disease. Recurrence rate after initial VTE up to 24.6% after 5 years. Clinical need to identify individuals at increased risk of recurrent VTE. VTE terminology. Provoked . An Educational Slide Set . American Society of Hematology 2020 Guidelines . for Management of Venous Thromboembolism. Slide set author: . Siraj . Mithoowani. MD, MHPE (McMaster University). Clinical Guidelines. March 2021. Agenda. Informed Consent. Using the VOICE Reporting Application. Consulting Additional Physicians. Doc Halo. Verbal/Phone Orders. Blood Usage. Focused Review. eCQM, eSTK-2, -6, eVTE-1, -2.